Aegis started coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $40.00 price target on the stock. Aegis’ price objective suggests a potential upside of 412.16% from the company’s current price. Recro Pharma Inc (NASDAQ:REPH) stock performance was -7.30% in last session and finished the day at $7.24. Traded volume was 36,875.00million shares in the last session and the average volume of the stock remained 47.50K shares. Recro Pharma Inc (NASDAQ:REPH) insider ownership is 42.40%.
Ignyta, Inc. (NASDAQ:RXDX), an oncology precision medicine biotechnology company, announced on 31 May 2014 that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Ignyta Inc (NASDAQ:RXDX) dropped -13.24 percent to $8.39 Monday on volume of 118,587.00million shares. The intra-day range of the stock was $8.30 to $9.61. Ignyta Inc (NASDAQ:RXDX) has a market capitalization of $164.27million.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) quiet period will expire on Tuesday, June 17th. Alder Biopharmaceuticals had issued 8,000,000 shares in its initial public offering on May 8th, AnalystRatingsNetwork.com reports. The total size of the offering was $80,000,000 based on an initial share price of $10.00. During Alder Biopharmaceuticals’ quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Alder Biopharmaceuticals Inc (NASDAQ:ALDR)’s stock on June 16, 2014 reported a decrease of -8.70% to the closing price of $18.57. Its fifty two weeks range is $9.50 -$22.95. The total market capitalization recorded $555.30million. The overall volume in the last trading session was 343,849.00million shares. In its share capital, ALDR has 29.90million outstanding shares.
Corcept Therapeutics Inc (NASDAQ:CORT) Director G Leonard Baker, Jr. purchased 103,386 shares of the company stock on the open market in a transaction dated Wednesday, June 11th. The shares were purchased at an average cost of $2.32 per share, with a total value of $239,855.52. Following the acquisition, the director now directly owns 578,389 shares in the company, valued at approximately $1,341,862. On Monday, shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) dropped -6.94% to close the day at $2.28. Company return on investment (ROI) is -74.10% and its monthly performance is recorded as 18.75%. Corcept Therapeutics Incorporated (NASDAQ:CORT) quarterly revenue growth is -38.21%.